{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:55:10Z","timestamp":1784138110512,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T00:00:00Z","timestamp":1702771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T00:00:00Z","timestamp":1702771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40261-023-01336-w","type":"journal-article","created":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T17:01:48Z","timestamp":1702832508000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of Long-Term Effectiveness and Safety of\u00a0Upadacitinib\u00a0for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Na\u00efve Patients"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-8190","authenticated-orcid":false,"given":"Maddalena","family":"Napolitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6734-1366","authenticated-orcid":false,"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Foggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-4278","authenticated-orcid":false,"given":"Katharina","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-4812","authenticated-orcid":false,"given":"Elena","family":"Pezzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Stingeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elettra","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-8392","authenticated-orcid":false,"given":"Vincenzo","family":"Picone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-2822","authenticated-orcid":false,"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,17]]},"reference":[{"issue":"4","key":"1336_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/all.14631","volume":"76","author":"D Siegels","year":"2021","unstructured":"Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. Allergy. 2021;76(4):1053\u201376. https:\/\/doi.org\/10.1111\/all.14631.","journal-title":"Allergy"},{"key":"1336_CR2","unstructured":"Rinvoq-European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq. Last access 4 Aug 2023."},{"issue":"3","key":"1336_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.025.","journal-title":"J Allergy Clin Immunol"},{"issue":"10290","key":"1336_CR4","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2.","journal-title":"Lancet"},{"key":"1336_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00798-0","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Ortoncelli M, Schena D, et al. Long-term effectiveness and safety of upadacitinib for atopic dermatitis\u00a0in a real-world setting: an interim analysis through 48 weeks of observation [published online ahead of print, 2023 Jun 15] [published correction appears in Am J Clin Dermatol. 2023 Aug 19]. Am J Clin Dermatol. 2023. https:\/\/doi.org\/10.1007\/s40257-023-00798-0.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"1336_CR6","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1111\/jdv.19011","volume":"37","author":"C Patruno","year":"2023","unstructured":"Patruno C, Fabbrocini G, Potestio L, Genco L, Napolitano M. Real-life efficacy and safety of upadacitinib in adolescents with moderate-to-severe atopic dermatitis unresponsive to dupilumab: a case series. J Eur Acad Dermatol Venereol. 2023;37(7):e901\u20133. https:\/\/doi.org\/10.1111\/jdv.19011.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1336_CR7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/jdv.18137","volume":"36","author":"M Napolitano","year":"2022","unstructured":"Napolitano M, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol. 2022;36(9):1497\u20138. https:\/\/doi.org\/10.1111\/jdv.18137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1336_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15788","volume":"35","author":"C Patruno","year":"2022","unstructured":"Patruno C, Fabbrocini G, De Lucia M, Picone V, Genco L, Napolitano M. Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib. Dermatol Ther. 2022;35(11): e15788. https:\/\/doi.org\/10.1111\/dth.15788.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1336_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/bjd.13662","volume":"172","author":"YA Leshem","year":"2015","unstructured":"Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353\u20137. https:\/\/doi.org\/10.1111\/bjd.13662.","journal-title":"Br J Dermatol"},{"key":"1336_CR10","unstructured":"EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side_en-0.pdf. Last access 23 Aug 23."},{"issue":"3","key":"1336_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaad.2023.05.033","volume":"89","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Ladizinski B, Prajapati VH, Laquer V, Fischer A, Eisman S, Hu X, Wu T, Calimlim BM, Kaplan B, Liu Y, Teixeira HD, Liu J, Eyerich K. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). J Am Acad Dermatol. 2023;89(3):478\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2023.05.033.","journal-title":"J Am Acad Dermatol"},{"key":"1336_CR12","doi-asserted-by":"publisher","first-page":"adv00872","DOI":"10.2340\/actadv.v103.5243","volume":"103","author":"CM Boesjes","year":"2023","unstructured":"Boesjes CM, Van der Gang LF, Zuithoff NPA, Bakker DS, Spekhorst LS, Haeck I, Kamsteeg M, De Graaf M, De Bruin-Weller MS. Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and\/or baricitinib: results from the BioDay registry. Acta Derm Venereol. 2023;103:adv00872. https:\/\/doi.org\/10.2340\/actadv.v103.5243.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1336_CR13","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s12325-023-02490-5","volume":"40","author":"A De Greef","year":"2023","unstructured":"De Greef A, Ghislain PD, de Montjoye L, Baeck M. Real-life effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults. Adv Ther. 2023;40(5):2509\u201314. https:\/\/doi.org\/10.1007\/s12325-023-02490-5.","journal-title":"Adv Ther"},{"issue":"23","key":"1336_CR14","doi-asserted-by":"publisher","first-page":"02645","DOI":"10.1016\/j.jaad.2023.08.059","volume":"S0190\u20139622","author":"JR Georgakopoulos","year":"2023","unstructured":"Georgakopoulos JR, Sheka D, Rankin B, Maliyar K, Rimke A, Prajapati VH, Yeung J. Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: a multicenter retrospective study. J Am Acad Dermatol. 2023;S0190\u20139622(23):02645\u201352. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.059.","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01336-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:32:19Z","timestamp":1704457939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01336-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,17]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01336-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,17]]},"assertion":[{"value":"6 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to conduct this study.\u00a0For some of the patients, AbbVie provided the drug upadacitinib through a compassionate use programme activated according to the DM 7\/9\/2017.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MN acted as speaker, consultant and advisory board member for Sanofi, Abbvie, Lilly, Leo Pharma and Pfizer; S.M.F. is speaker of Novartis and Sanofi Genzyme, is principal investigator for Eli Lilly, AbbVie, Sanofi Genzyme, and is an advisory member of Sanofi Genzyme; L.S. acted as speaker and board member for Sanofi-Genzyme; C.P. acted as investigator, speaker, consultant and advisory board member for AbbVie, Eli Lilly, Novartis, Pfizer, Pierre Fabre and Sanofi. The other authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of this study was obtained by the Local Ethics Committee (Prot. N. 116\/20, approved on December 5, 2022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\u00a0approval"}},{"value":"The patients in this manuscript have given written informed consent to participate in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patients in this manuscript have given written informed consent to publication of their case details.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data are reported in the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made substantial contribution to this manuscript and in detail: MN conceptualized, designed the study, analysed and interpretated the data and drafted the article; SMF, KH, EP and EA acquired data and clinically managed patients; LF and VP performed statistical analysis of data with graphical and tabular conceptualization; LS and CP reviewed the article critically for important intellectual content. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}